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Abstract
Background: Triple negative breast cancers (TNBC) possess cell dedifferentiation characteristics, carry out activities
connate to those of cancer stem cells (CSCs) and are associated with increased metastasis, as well as, poor clinical
prognosis. The regulatory mechanism of this highly malignant phenotype is still poorly characterized. Accruing
evidence support the role of non-coding RNAs (ncRNAs) as potent regulators of CSC and metastatic gene
expression, with their dysregulation implicated in tumorigenesis and disease progression.
Methods: In this study, we investigated TNBC metastasis, metastasis-associated genes and potential inhibitory
mechanisms using bioinformatics, tissue microarray analyses, immunoblotting, polymerase chain reaction, loss and
gain of gene function assays and comparative analyses of data obtained.
Results: Compared with other breast cancer types, the highly metastatic MDA-MB-231 cells concurrently exhibited
increased expression levels of Lysine-specific demethylase 5B protein (KDM5B) and long non-coding RNA (lncRNA),
MALAT1, suggesting their functional association. KDM5B-silencing in the TNBC cells correlated with the
upregulation of hsa-miR-448 and led to suppression of MALAT1 expression with decreased migration, invasion and
clonogenic capacity in vitro, as well as, poor survival in vivo. This projects MALAT1 as a mediator of KDM5B
oncogenic potential and highlights the critical role of this microRNA, lncRNA and histone demethylase in cancer
cell motility and metastatic colonization. Increased expression of KDM5B correlating with disease progression and
poor clinical outcome in breast cancer was reversed by hsa-miR-448.
Conclusions: Our findings demonstrate the critical role of KDM5B and its negative regulator hsa-miR-448 in TNBC
metastasis and progression. Hsa-miR-448 disrupting KDM5B-MALAT1 signalling axis and associated activities in TNBC
cells, projects it as a putative therapeutic factor for selective eradication of TNBC cells.
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Breast carcinoma is a huge socio-economic and clinical
challenge, being the second most diagnosed cancer for both
sexes combined, the most prevalent female malignancy and
the leading cause of female mortality worldwide [1]. Recent
data approximates the global cancer mortality at 7.6 mil-
lion, and breast cancer with an annual incidence of over
one million newly diagnosed cases, accounts for over 6 %
of this mortality [2].
Breast cancer, like many polyetiologic human patholo-
gies, is a product of cumulative genetic, epigenetic, som-
atic, and endocrine aberrations. The polyaetiologism and
constitutive complexity of breast cancer presents a chal-
lenge for prevention and treatment of breast malignan-
cies. There are five subtypes of breast cancer [3], and of
these, the hormone receptor-negative basal epithelial,
commonly referred to as ‘triple negative breast cancer’
(TNBC), is the most aggressive, most common among
younger women of African-American and Latina ances-
try and has the worst clinical prognosis [4]. TNBCs are
very invasive breast carcinomas lacking estrogen (ER),
progesterone (PR), and human epidermal growth factor
receptors (HER2) [5] and are associated with enhanced
cellular proliferation, early disease recurrence, and poor
overall survival [6]. However, despite increased know-
ledge of the aetiology and mechanism of this breast can-
cer type, developing an effective anti-TNBC therapeutic
strategy is still a clinical challenge.
Long non-coding RNAs (lncRNAs) are transcribed
RNA molecules longer than 200 nucleotides and en-
dogenously expressed in mammalian cells. Accumulat-
ing evidence indicate that lncRNAs, once considered to
be genomic anomalies and functionless, do play signifi-
cant roles in both physiologic and pathologic human
conditions through their regulation of defined target
mRNA expression, and their post-transcriptional epi-
genetic modulation [7]. Following the work of Okazaki
et al., which demonstrated that many mammalian tran-
scriptome are non-protein coding and defined lncRNAs
as a significant class of these transcripts [8], it is esti-
mated that about 11 % of the approximately 180,000
large mouse transcriptome are probably protein-coding
[9], and that the number of lncRNAs far exceeds
protein-coding mRNAs in the mammalian transcriptome
[10]. Despite the heightened interest in lncRNA biology,
their precise function in cellular processes and promoter
regulation remains widely undetermined, thus, our study
of the functional significance of lncRNAs, their genomic
role and their epigenetic regulation.
We hypothesized that the 8.6 kb lncRNA MALAT1 is
epigenetically-regulated, and that this is associated with
the modulation of various oncogene expression and ac-
tivities including cell proliferation, migration, invasion,
and metastasis. This is consistent with documentedevidence that transient MALAT1 overexpression en-
hanced tumor proliferation in cell lines and xenograft
tumor formation in nude mice, while its attenuation re-
sulted in reduced tumorigenicity [11, 12].
KDM5B belongs to the histone lysine demethylase
family, with the ability to cause transcriptional silencing
by specifically demethylating di- and tri- methylated
lysine 4 of histone 3 of their target genes, and is overex-
pressed in several carcinomas, including gastric cancer,
glioma and breast cancer [13, 14]. Observing a concomi-
tant increase in MALAT 1 and KDM5B expression as
breast cancer progresses, we investigated and validated
the hypotheses that MALAT 1 interacts with KDM5B,
and that the MALAT1 expression is positively regulated
by that of KDM5B in the highly malignant and clinically
challenging TNBC. In addition, since highlighting the
problem without proffering a solution was not the intent
of our work, we systematically screened for an effective
therapeutic approach that not only targets KDM5B or
MALAT1 expression and/or activities, but also improve
clinical outcome, using a combination of small molecule
inhibitors, genetic ablation or sncRNA.Methods
Tissue samples
Twenty human breast tumor tissue samples collected dur-
ing reduction mammoplasty and classified into various
histological subtypes were obtained from archived samples
of the Tissue Bank at Taipei Medical University- Shuang
Ho Hospital (TMU-SHH). All of the patients gave signed,
informed consent for their tissues to be used for scientific
research. Recommendations of the Declaration of Helsinki
for biomedical research involving human subjects were
also followed. Ethical approval for the study was obtained
from Joint Institutional Review Board of the Taipei Medical
University (approval number: 201202007/ B201112003).Cell lines and culture
The panel of selected cell lines used in this study
consisted of non-tumorigenic MCF-10A and non-
metastatic MCF-7 breast myoepithelial cell lines, as
well as six breast carcinoma cell lines, MDA-MB-
231, MDA-MB-453, HS578T, T47D, AU565 and
SKBr3. All cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA)
and cultured according to established standard condi-
tions using RPMI1640 supplemented by 5 μg/ml insulin
(Invitrogen, Thermo Fisher Scientific Inc., Grand Island,
NY, USA), 10 ng/ml EGF (Sigma), 10 % FBS (Sigma),
Penicillin/Streptomycin (Sigma) in a humidified 5 %
CO2 incubator. Cells were passaged at 90 % confluence
and the medium changed every 48–72 h.
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For KDM5B knockdown, MDA-MB-231 cells were in-
fected with KDM5B short hairpin RNA (shRNA,
clone ID -TRCN0000329952) targeting the sequence
ATCGCTTGCTTCATCGATATT, GTGCCTGTTTACC
GAACTAAT, or GCACCAAATTAGAGAGTCT, for
clones I, II or III respectively, or vector (pLKO_TRC005),
from National RNAi Core Facility, Academia Sinica,
Taiwan, then shRNA expressing cells were selected with
1ug/ml puromycin. KDM5B overexpression in MCF10A
cells was via transfection of the human KDM5B
(NM_006618.3) cDNA sequence cloned into pCMV6-
Entry vector (pCMV-KDM5B; E2384, GeneCopoeia,
Inc. Rockville, MD, USA) using LipofectAMINE PLUS
reagent (Life Technologies, Thermo Fisher Scientific
Inc., NY, USA). MCF10A cells were seeded and cultured
in 35 mm diameter dishes until 80 % confluence. On the
day of transfection, 1 mg of DNA diluted in 100 μl of
serum-free medium, and 6 μl of LipofectAMINE PLUS
regents were then added. The DNA-PLUS mix was in-
cubated for 20 min at room temperature, and then 4 μl
of LipofectAMINE reagent was added and incubated for
an additional 20 min. After incubation, the cells were
washed with serum-free medium twice and 800 μl of
serum-free transfection medium. The DNA-PLUS–Li-
pofectAMINE reagent mix was then added to the cells
and incubated at 37 °C in 5 % humidified CO2 incubator
for 3 h. After 3 h, recovery medium with 10 % FBS was
added till final volume of 2 ml and incubated. After in-
cubating overnight, the recovery medium was suctioned
and fresh DMEM medium containing serum and antibi-
otics added.
RNA extraction, RT-PCR and real time PCR
Total RNA was isolated using TRI Reagent (Sigma) ac-
cording to manufacturer’s protocol. RNeasy Mini Kit
was used for RNA purity optimization. Total RNA con-
centration was determined using NanoDrop ND1000
spectrophotometer (Nyxor Biotech, Paris). 1 μg of total
RNA was transcribed reversely with 2 μg of random hex-
amers (Amersham, Taipei, Taiwan) and Superscript III
reverse transcriptase (Invitrogen, Thermo Fisher Scien-
tific Inc., Grand Island, NY, USA) according to manufac-
turer’s instructions. DEPC-treated water was used to
dilute cDNA 100 folds and stored at −20 °C. Real-time
PCR was done using SYBR Green PCR Master Mix
using inbuilt System Software (Applied Biosystems, Life
Technologies, Grand Island, NY, USA), 200nM forward
and reverse primers, and cDNA equivalent of 0.5ug
RNA. The triplicate PCR reaction conditions were as fol-
lows: 25 °C–5 min, 42 °C–60 min, 70 °C–5 min; total
45 cycles of 70 °C–10 min. 20ul PCR product was loaded
to 1.5 % SYBR Green agarose gel for electrophoresis and
checked under UV light. Gene expression was normalisedto GAPDH and altered expression measured relative to
the control (MDA-MB-231 Vector; shKDM5B-vector in-
fected MDA-MB-231 cells).
Western blot analysis
Total cell lysates were prepared and analyzed by western
blot assay. Primary antibodies used included KDM5B
polyclonal antibody (H00010765-A01; Abnova, Neihu
District, Taipei City, Taiwan), Oct 4 Rabbit mAb (C30A3;
Cell Signaling Technology, Inc., Beverly, MA, USA),
Survivin (FL-142: sc-10811; Santa Cruz Biotechnology,
Inc., Dallas, Texas, USA) and GAPDH. Secondary anti-
bodies were Alexa Fluor 680-conjugated affinity-
purified anti-mouse or anti-rabbit IgG (Invitrogen,
Thermo Fisher Scientific Inc., Grand Island, NY, USA)
detected using the UVP Imaging.
Colony formation assay
2 × 104 cells were seeded into a 6-well cell culture plate
and incubated for 2 weeks at 37 °C after treatment.
Then, cells were washed twice with PBS, fixed with cold
methanol, stained with 0.005 % crystal violet, washed
and air dried. Colonies were then counted. In each well,
the total colonies with a diameter ≥ 100 μm were
counted over 5 randomly selected fields in triplicate
assays.
Matrigel invasion assay
Using the 24-well plate Transwell system, 3 × 104 cells
were seeded into the upper chamber of the insert (BD
Bioscience, 8 μm pore size) containing medium without
serum, and medium containing 10 % FBS in the lower
chamber served as chemoattractant. After 24 h of incu-
bation, medium was discarded, cells on filter membrane
were fixed with 3.7 % formaldehyde for 1 h and stained
with crystal violet staining solution, and cells on the
upper side of the insert were removed with a cotton
swab. The migrated cells were visualized and migratory
capacity was evaluated as the total number of cells on
the lower surface of the membrane, as determined by
microscopy.
MiRNA profiling and secondary structure prediction
We used TargetScan [15], PicTar [16] and miRANDA
[17] for miR profiling and target sorting. The M-FOLD
program v 2.3, [18] was employed to predict the second-
ary structure of hsa-miR-448. The prediction was done
as earlier described by Bellucci M and colleagues [19].
Access and probe of online cancer data set
Publicly available and freely accessible online cancer data
repositories used in this study include TCGA, Oncomine,
GEO and CCLE. The Cancer Genome Atlas (TCGA) data-
set used was the breast invasive carcinoma (BRCA)-
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and analyzed the TGCA dataset using the UCSC Cancer
Browser [21] and via the Oncomine interface [22]. We
also used dataset GSE3494, platforms GPL 97 from
the Gene Expression Omnibus (GEO) [23] consisting
of freshly frozen breast tumors from a cohort of 315
women which represents 65 % of all breast cancers
resected in Uppsala County, Sweden, from 1/1/1987
to 31/12/1989,with their estrogen receptor (ER) sta-
tus determined using biochemical assay.Immunohistochemical staining and statistical analyses
A total of 270 patients diagnosed with breast carcin-
oma between January 1, 2005 and December 31,
2010 in Mackay Memorial Hospital (Taipei City,
Taiwan) were enrolled for the study. All of the patients
gave signed, informed consent for their tissues to be used
for scientific research. Recommendations of the Declar-
ation of Helsinki for biomedical research involving human
subjects were also followed. Ethical approval for the study
was obtained from Joint Institutional Review Board of
the Mackay Memorial Hospital (approval number:
11MMHIS154). Patients’ clinical records were reviewed
to determine tumor stage at the time of diagnosis and out-
come. H&E–stained sections of the mammoplasty speci-
mens were reviewed to select representative areas of the
tumor to carry out KDM5B immunohistochemical detec-
tion. The working dilution was 1:200. KDM5B immuno-
histochemistry was carried out using tissue microarray
(TMA) on an automated system for immunostaining
(Dako Autostainer), with antigen retrieval at high pH. We
graded the intensity of the membrane and cytoplasmic
staining as absent, weak, moderate, or intense, after
stained sections were counterstained with hematoxylin.
However, for subsequent statistical analysis we reclassified
the cases as high (moderate or intense) or low (null or
weak staining similar to control areas of normal breast tis-
sue). In all cases, sections from normal breast tissue bor-
dering the tumor site were used as negative controls. We
carried out survival analysis using the Cox univariate and
multivariate analyses of proportional hazards model for
KDM5B status and selected clinicopathological predictors
of outcome. The multivariate model was produced by
assessing KDM5B status with other baseline covariates of
clinical relevance, such as tumor size, body weight, lymph
node metastasis, and hormone receptor status. Log-rank
test was used to evaluate significant survival probability
differences, while 95 % confidence interval (CI) and
hazard ratio (HR) were derived from the regression coeffi-
cients. Data were expressed as mean ± standard error of
mean, and compared using one way ANOVA and
Student’s t-test. p < 0.05 was considered statistically
significant.Results
Upregulation of KDM5B expression in human breast
cancer tissues and cell lines
To understand the biofunctional significance of KDM5B
in human breast cancer, using bioinformatics approach,
we accessed and probed the TCGA invasive lobular and
ductal breast carcinoma dataset consisting of 593 sam-
ples via the Oncomine interface. Analysing the expres-
sion of KDM5B in this dataset, we observed that
KDM5B expression in the invasive lobular breast cancer
samples was upregulated by about 2.44-fold (p < 0.001,
Fig. 1a) compared to the normal breast tissue, while in
the invasive ductal breast cancer set, KDM5B was over-
expressed 1.95-folds higher than the normal breast tissue
group (p < 0.001, Fig. 1b). Using immunohistochemical
staining, we confirmed the endogenous expression of
KDM5B in breast cancer samples and correlative ana-
lysis showed that KDM5B expression level positively cor-
related with tumor histological grade (p < 0.001), with
highest expression in grade IV (Fig. 1c). Furthermore,
our comparative analysis of the expression levels of
KDM5B in 23 paired breast carcinoma and adjacent
non-neoplastic tissues from TMU-SHH breast cancer
patients’ cohort using western blot showed that the ex-
pression levels of KDM5B were elevated in 21 of 23 cases
of breast cancer specimens compared with those of adja-
cent non-neoplastic tissues (p < 0.001) (Fig. 1d & e). In
addition, we assessed the expression levels of KDM5B in
breast cancer cell lines. Result indicated elevated expres-
sion level of KDM5B in the TNBC cell lines compared to
their counterpart non-TNBC cell lines. The highly meta-
static MDA-MB-231 and MDA-MB-453 cells exhibited
the strongest expression of KDM5B (Fig. 1f). These results
indicate that increased KDM5B expression is character-
istic of highly malignant human breast cancer cells and
tissues, as well as suggest its involvement in breast car-
cinoma aggressive phenotype and progression.
High KDM5B expression is significantly associated with
clinical outcome in breast carcinoma, in vivo
To evaluate the prognostic relevance of the KDM5B ex-
pression in the cohorts, cases were stratified as high and
low. Our initial discovery cohort consisting of only 23
subjects, was considered small and lacked proper docu-
mented follow-up, therefore, the relationship between
KDM5B expression and tumor progression using the ini-
tial cohort data was subjected to further exploration in a
larger, independent validation cohort of 270 breast can-
cer patients TMA with longer follow-up, which included
overall disease-specific survival. In our validation cohort,
KDM5B was strongly expressed in 49.2 % (n = 270) of
the breast cancer samples (Fig. 2a). Both univariate and
multivariate analyses using the Cox proportional hazards
model showed that KDM5B expression, lymph node
Fig. 1 KDM5B expression is upregulated in human breast cancer tissues and cell lines. KDM5B is overexpressed in triple negative TGCA (a)
invasive lobular breast cancer, and (b) invasive ductal breast cancer tissues, compared to their counterpart normal breast tissues. 1, normal breast
tissue; 2, invasive breast carcinoma (c) Representative photomicrograph of immunohistochemical staining of KDM5B in human breast cancer
tissues showed that KDM5B expression occurs preferentially in TNBC late tumor stage samples. Photographs were taken at 200× magnification.
Western blot showing KDM5B expression in (d, e) paired tumor: non-tumor human breast samples. f Western blot analysis of KDM5B expression
in 7 different breast cancer cell lines. KDM5B is strongly expressed in TNBC cell lines, MDA-MB-231, MDA-MB-453 and HS-578 T. GAPDH and
α-tubulin were used as loading control. Experiments were done in triplicate and quantified by ImageJ densitometry. KDM5B, lysine specific
demethylase 5B protein; T, tumor; NT, non-tumor; DCIS, ductal carcinoma in situ; 231, MDA-MB-231; 453, MDA-MB-453
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of breast cancer biochemical and clinical outcome
(Table 1). χ2 correlative analysis of the KDM5B expres-
sion and clinicopathological parameters revealed signifi-
cant associations between high KDM5B expression and
larger tumor size (p = 0.005, Table 2). Patients withhigher KDM5B expression had significantly poorer prog-
nosis compared to those with low expression, as assessed
by overall survival (multivariate: HR 1.68, 95 % confi-
dence interval (CI) 1.02–2.75, p = 0.04; univariate: HR
1.63, 95 % confidence interval (CI) 1.01–2.65, p = 0.047,
Table 1). Adjunct to our data, we further analysed triple
Fig. 2 Correlation of KDM5B expression with patients’ survival. Kaplan-Meier curves with univariate analyses (log-rank) of KDM5B expression in
triple negative breast cancer patients stratified as high and low KDM5B, where high KDM5B was defined as >80 % average nuclear expression,
while low KDM5B <80 % nuclear expression (*P < 0.05). a OS according to nuclear KDM5B immunohistochemical expression in TNBC tissues from
the Mackay Memorial Hospital cohort of 270 patients. b OS according to nuclear KDM5B immunohistochemical expression in TNBC tissues from the
GEO breast cancer cohort. c DMFS according to nuclear KDM5B immunohistochemical expression in TNBC tissues from the GEO breast cancer cohort.
d RFS according to nuclear KDM5B immunohistochemical expression in TNBC tissues from the GEO breast cancer cohort. OS, overall survival; DMFS,
distance metastasis-free survival; RFS, relapse-free survival
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gene expression omnibus, GEO – Affymetrix HGU133A
and HGU133 + 2, consisting of 1809 patients [14]. Con-
sistent with our findings, in multivariate analysis, highKDM5B expression profile was a significant predictor
of poor overall survival, OS (HR 2.44, 95 % CI 1.1–5.43,
p = 0.023), distance metastasis-free survival, DMFS (HR
3.34, 95 % CI 1.44–7.78, p = 0.0029) and relapse-free
Table 1 Univariate and Multivariate analyses using Cox proportion hazards model of overall survival of all hormone negative breast
cancers (n = 270)
Univariate analysis Multivariate analysis
Parameters HR 95 % CI P value HR 95 % CI P value
KDM5B expression High vs Low 1.635 1.007 2.653 1.678 1.025 2.749
Tumor size 1.009 0.999 1.02 0.0796 1.011 0.999 1.023 0.0761
Body weight 1.001 0.975 1.028 0.9378 0.998 0.972 1.025 0.9059
Height 1.021 0.993 1.05 0.136 1.025 0.995 1.055 0.1005
BMI 1.001 0.873 1.147 0.99 1.054 0.915 1.215 0.4625
Lymph nodes metastasis 1.016 1.001 1.031 1.027 1.006 1.048
ER status 1.447 0.889 2.354 0.1371 1.395 0.839 2.318 0.1994
HER2 status 0.907 0.548 1.499 0.702 0.835 0.493 1.414 0.5014
Red indicates p value < 0.05
HR hazard ratio, CI confidence index, BMI body-mass index, ER estrogen receptor, HER2 human epidermal growth factor receptor 2
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Fig. 2b–d), projecting KDM5B overexpression as an in-
dependent predictor of poor clinical outcome.
KDM5B enhances the proliferation and maintenance of
aggressive breast cancer cells malignant phenotype
To investigate the effect of KDM5B on the prolifera-
tion and malignant phenotype of breast carcinoma
cells, we performed cell proliferation, mammosphere
formation and colony formation assays. We con-
firmed previous reports that the proliferation of
breast cancer cells was inhibited by the conditions in
which KDM5B expression and/or activity was attenu-
ated on the premise that increased invasiveness of
the triple negative breast cancer cells was augmented
by proliferation of these cancer cells. There was in-
creased proliferation (Fig. 3a), mammosphere gener-
ation (Fig. 3b) and colony formation (Fig. 3c) in the
KDM5B-positive vector breast cancer cells, while








≤3 85 (62.04 %) 60(45.11 %) 7.78
>3 52(37.96 %) 73(54.89 %)
Lymph nodes
≤18 65(47.45 %) 65(48.87 %) 0.06 0.814
>18 72(52.55 %) 68(51.14 %)
Red indicates p value < 0.05reduced proliferation, mammosphere formation and
clonogenicity ability. To determine if KDM5B was
sufficient for the activation of the increased TNBC
oncoagression observed, we further evaluated the ex-
pression of KDM5B, c-Myc (a metastatic factor and
mesenchymal marker) and other EMT markers in
breast cancer tissues and cell lines. Our data revealed a
similar expression pattern for KDM5B and c-Myc in
both clinical samples (Fig. 3d). Positive correlation was
also noted for the expressions of KDM5B and the
survival factor, Survivin, as well as with EMT markers,
c-Met, Slug and N-Cadherin, while as anticipated E-
Cadherin exhibited a reverse pattern of expression
compared with KDM5B (Fig. 3e). Thus, we inferred
that the difference in the malignant invasive potential
of the breast cancer cells was due to their differential
KDM5B expression.Silencing of KDM5B markedly reduced migration and
invasive potential of TNBC cells
KDM5B-expressing TNBC cells showed enhanced cell in-
vasion in the transwell matrigel invasion system. Using
the short hairpin RNA (shRNA) gene-silencing approach,
we determined the knockdown efficiency of KDM5B at
both protein (Fig. 4a) and messenger (Fig. 4b) levels. We
evaluated the effect of KDM5B expression on tumor cell
motility with or without KDM5B knockdown. There was
a significant lag in migration (Fig. 4c, d) and invasiveness
(Fig. 4e, f ) in the KDM5B-silenced MDA-MB-231 cells,
compared to vector control. These data indicate that
KDM5B enhances the invasion and migration of TNBC
cells, while its attenuation genetically or via small molecu-
lar inhibitors has a converse effect.
Fig. 3 KDM5B enhances the proliferation and maintenance of TNBC cells malignant phenotype. a Proliferation assay showing that KDM5B knockdown
inhibited cell proliferation, (b) silencing KDM5B suppressed the ability of the shKDM5B infected MDA-MB-231 cells to form mammospheres, and
(c) colony formation assay showed that vector-infected cells possessed greater clonogenicity than their counterpart shKDM5B infected MDA-
MB-231 cells. The experiments were carried out in triplicate. Scale bar: 200 μm. d Western blot showed that in human breast tissue samples
KDM5B expression is higher in the TNBC tissues, compared to their non-TNBC counterparts and (e) the expression profile of KDM5B in different
breast cancer cell lines, is similar to that of Survivin, c-Met, slug, c-Myc and N-cadherin, and converse to that in E-cadherin. GAPDH and a-tubulin
were used as loading control. KDM5B, lysine specific demethylase 5B protein; 231, MDA-MB-231; 453, MDA-MB-453; **P < 0.01
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enhanced migration, and acquisition of CSC-like phenotype
in non-tumorigenic MCF-10A breast cancer cell line
In analogous experiments, we investigated the effect
of induced KDM5B expression on the oncogenic po-
tential of non-tumorigenic MCF-10A myoepithelial
cells, using the western blot, transwell matrigelinvasion and mammosphere formation assays. We ob-
served that induced expression of KDM5B yielded an
upregulation of snail and vimentin protein expression
(Fig. 5a), as well as approximately 1.58- and 1.45- fold
increase in snail and vimentin transcript expression in
the MCF-10AoeKDM5B cells relative to MCF-10A
WT. In addition, MALAT1 transcript expression and/or
Fig. 4 Silencing of KDM5B markedly reduces the migration and invasive potential of TNBC cells. a, b KDM5B expression in MDA-MB-231
mammosphere, cells stably expressing KDM5B vector or shKDM5B assessed by western blot analysis and RT-PCR. GAPDH serves as loading controls.
c, d MDA-MB-231 control vector or KDM5B-depleted cells were subjected to a wound healing in vitro migration assay as described under Materials
and methods. Representative photomicrographs at indicated time points from three independent experiments, each performed in triplicate wells, are
shown. Magnification: × 20. The cells were allowed to migrate after wounding for 12 h. The extent of wound recovery was determined by measuring
the distance between migrating cellular fronts at 5 randomly selected points and finding the average. Migration was significantly inhibited in
shKDM5B-expressing MDA-MB-231 cells as compared with that in control wild-type cells. Column: Mean of three experiments; bar: standard error,
p-value was determined by student’s t-test (*P < 0.05; ***P < 0.001). e, f KDM5B ablation in MDA-MB-231 cells significantly attenuated invasion of
shKDM5B MDA-MB-231 cells as compared to control wild-type and vector cells. Column: Mean of three experiments. Bar: standard error P-value was
determined by Student’s t-test (***P < 0.001). KDM5B, lysine specific demethylase 5B protein; shRNA, short hairpin RNA
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2.18-folds when compared with their un-induced MCF-
10A WT counterparts (Fig. 5b, Additional file 1: Table S1
and Additional file 2: Figure S1). We noted that induction
of KDM5B expression in the MCF-10A cells (MCF-
10AoeKDM5B) enhanced their migratory ability byapproximately 10-fold in comparison to their wild type
counterpart, MCF-10A WT (Fig. 5c, d). Of note is our
finding that forced KDM5B expression in MCF-10A OE
cells induced the acquisition of cancer stem cell-like
phenotype in the KDM5B-deficient, non-tumorigenic
MCF-10A cells, as evidenced by their markedly increased
Fig. 5 Forced KDM5B expression induced tumorigenicity, enhanced migration, and acquisition of CSC-like phenotype in non-tumorigenic
MCF-10A breast cancer cell line. a Western blot showing cytoplasmic and nuclear expression profile of KDM5B compared with that of snail and
vimentin in MDA-MB-231 WT, MDA-MB-231 KD, MCF10A WT and MCF10A OE. b A representative RT-PCR result showing transcript expression of
KDM5B, MALAT1, snail, vimentin, and miR-448. GAPDH served as loading or internal control. c Mammosphere formation assay showing the effect
of induced KDM5B expression in MCF10A cells. MCF10A WT and MDA-MB-231 WT cells were used as negative and positive control, respectively.
d, e Quantitative box-plots depicting mammosphere formation ability and efficiency in MDA-MB-231WT, MDA-MB-231shKDM5B, MCF10AWT and
MCF10AoeKDM5B. f, g Representative Photomicrogram and bar chart of invasion assays showing the effect of KDM5B overexpression in MCF10A
cells. ***P < 0.001
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gous to those formed by the highly malignant TNBC cell,
MDA-MB-231, which served as our positive control
(Fig. 5e). The mammosphere formation efficiency (MFE) of
the MCF10A WT was significantly augmented by induced
expression of KDM5B from 10 ± 0.004 % to 82 ± 0.04 %,while as anticipated the MFE of MDA-MB-231 WT cells in
the mammosphere culture was markedly suppressed by
shKDM5B from 79 ± 0.04 % to 26 ± 0.02 % (p < 0.001)
(Fig. 5f). In addition, the size of MDA-MB-231-derived
mammospheres decreased by shKDM5B, as evidenced by
significantly lesser number of proper mammospheres
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while on the other hand, that of the MCF10AoeKDM5B
increased to 19.63 ± 0.04 (p < 0.001), compared to the
0.21 ± 0.4 in its wild type counterpart (Fig. 5g). This is
consistent with our earlier findings that suggested that
KDM5B plays a critical role in the formation and main-
tenance of breast cancer stem cells (BCSCs). Collectively,
these data indicate that KDM5B expression is sufficient
for induction of pluripotency in breast, critical for self-
renewal of breast tumor cells, effectively activates meta-
static factors, initiates EMT and invariably is crucial for
the BCSCs-mediated invasiveness of hitherto non-
tumorigenic MCF10A cells.KDM5B induces the expression of MALAT1 and its
effector metastasis- associated genes in triple negative
breast carcinoma cells
Our data suggest a critical role for MALAT1 in the
KDM5B-mediated malignant phenotype in TNBC cells.
In parallel experiments, we sought to verify our obser-
vation that KDM5B acts as an epigenetic regulator of
MALAT1, and MALAT1 in turn, modulates down-
stream snail and vimentin. Employing bioinformatics
approach, we evaluated the correlative associatedness
of KDM5B and MALAT expression in malignant breast
cancer. We probed the TCGA illuminaHiSeq breast in-
vasive carcinoma dataset consisting of 1182 human
breast tumor cases, and demonstrated notable similar-
ity in gene expression levels and proportion in the
probed samples (Fig. 6a & b), while our qRT-PCR dem-
onstrated that downregulation of KDM5B expression
via shRNA induced a significant concomitant suppres-
sion of MALAT 1 expression (Fig. 6c–e). Using same
database, we performed a comparative evaluation of the
expression profile of KDM5B, MALAT1 and selected
metastasis, stemness, survival and drug resistance genes
in TNBC and non-TNBC. This showed a preferential
expression of KDM5B and its associated effector genes
or substrates, in TNBC compared to their non-TNBC
counterparts (Additional file 3: Figure S2). Further-
more, our western blot results corroborated the bio-
informatics and qRT-PCR findings, showing that
KDM5B signalling induced MALAT1 activity and con-
sequently induced the expression of the metastasis-
associated genes, snail and vimentin in the vector con-
trol (Vec) and spheroid (Vec Sp) cells, compared to
their KDM5B-silenced counterparts (shIII and shIII Sp)
(Fig. 6f ). These findings are consistent with previous
results where induced expression of KDM5B in
MCF10A cells enhanced the expression of snail and
vimentin (Fig. 5b), and thus, suggest that KDM5B pro-
motes TNBC malignant phenotype by modulating
MALAT1 activity.KDM5B interacts with MALAT1 to modulate its expression
in triple negative breast carcinoma cells and
consequently facilitate invasion and associated metastatic
activities
To better understand the functional association between
KDM5B and MALAT1, as well as the underlying mechan-
ism by which the later mediates the activity of the former,
we assessed the propensity for KDM5B-MALAT1 inter-
action (Fig. 7a), the strong interactability or complex form-
ability of KDM5B with MALAT1 using the sequence-based
RNA-Protein interaction prediction (Fig. 7b–d), and the
strength of such interaction (Fig. 7e–g), patterned after
recently published bioinformatics approach [24–26].
KDM5B protein sequence used was the NCBI Ref. Seq.
NP_006609.3 while the sequence of MALAT1 used was
NCBI Ref. Seq. NR_002819.2. We showed that based on
the Random Forest (RF) and Support Vector Machine
(SVM) classifier prediction, the probability of interaction
between MALAT1 and KDM5B ranged between 85 and
99 % (Fig. 7a).
Further, to appreciate the architectural viability of
KDM5B-MALAT1 complex formation, we carried out
ligand docking coupled with limited binding site analysis
using the educational-use-only version of GUI PyMOL
software [27]. Figure 7b–d show alternative 3D molecu-
lar visualization of the KDM5B-MALAT1 complex.
While Fig. 7c is post-SCULPTing, an interactive process
that allowed us to manipulate the molecular structures
of KDM5B and MALAT1 while computing associated
molecular mechanics in real time, Fig. 7d is a Mol
script/Raster3D input, using a rapid Z-buffer algorithm
to generate high quality pixel image of the KDM5B-
MALAT1 complex, with characteristic shadowing and
non-shadowing light source, transparency, specular
highlighting, as well as Phong-shaded molecular sur-
faces. We then utilized the catRAPID graphic RNA-
Protein interaction validation tool [28] for validation of
our data. There was significant interaction activity be-
tween KDM5B and MALAT1 based on the generated
heat map (Fig. 7e), and KDM5B-MALAT1 interaction
strength of 93 % (Fig. 7f & g) estimated from the inter-
action propensity rank of binding regions in the positive
set (10201 interacting pairs) using the catRAPID strength
tool.
KDM5B is a functional target of hsa-miR-448, thus,
aberrant downregulation of the later in
KDM5B-overexpressing triple negative breast carcinoma
tissues and cell lines
Since the intent of our work was to proffer a clinically
applicable solution and not just highlight a problem, we
used a combination of small molecule inhibitors, genetic
ablation or sncRNA to systematically screen for an ef-
fective therapeutic approach that targets KDM5B or
Fig. 6 KDM5B induces the expression of MALAT1 and its effector metastasis-associated genes in TNBC cells. a, b TCGA illuminaHiSeq breast
invasive carcinoma dataset analysis show similar KDM5B and MALAT1 gene expression levels and proportion in 1182 clinical samples probed. c–e
The effect of KDM5B knockdown on the expression of KDM5B or MALAT1 transcripts using quantitative RT-PCR. f Western blot of control, shKDM5B
transfected, vector-generated mammospheres and shKDM5B-III transfected spheroid cells. Cellular lysates containing 20 μg of total protein were
subjected to western blotting using the indicated antibodies. The data are representative of triplicate experiments. ***p < 0.001; 231 KDM5B II/III,
shKDM5B infected MDA-MB-231 clone II/III cells; ShIII, shKDM5B infected MDA-MB-231 clone III cells; ShIII Sp, mammospheres generated from shKDM5B
infected MDA-MB-231 clone III cells; Vec Sp, mammospheres generated from vector infected MDA-MB-231 cells
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matics approach, we also probed available freely access-
ible miR databases for miRs associated with KDM5B
expression and came up with a panel of miRs (data not
provided). From our literature-based functional analyses,
deductive association, and miR - mRNA alignment, we
narrowed down on hsa-miR-448 (Fig. 8). Our bioinfor-
matics prediction was validated by using the sequence-
based RNA-protein interaction algorithm described earl-
ier in section (KDM5B interacts with MALAT1 tomodulate its expression in triple negative breast carcin-
oma cells and consequently facilitate invasion and asso-
ciated metastatic activities). We found that the 5′ end of
hsa-miR-448 perfectly aligned with and bonded to the 3′
end of KDM5B (Fig. 8a & b), with a RF and SVM inter-
action classifier score of 70 and 81 % respectively
(Fig. 8c). Notable is the finding that the hsa-miR-448 -
KDM5B – MALAT1 complex formability ranged from
75 to 99.7 % based on RF and SVM classification
(Fig. 8c). Our miRs screening showed that hsa-miR-448
Fig. 7 KDM5B interacts directly with MALAT1 to modulate its expression in triple negative breast carcinoma cells. a Sequence-based prediction of
MALAT1-KDM5B interaction, with random forest, RF classifier score of 0.85 and support vehicle machine, SVM classifier score of 0.99. * Interaction
probabilities generated by RPISeq range from 0 to 1. In performance evaluation experiments, predictions with probabilities > 0.5 were considered
“positive,” i.e., indicating that the corresponding RNA and protein are likely to interact. b PyMOL view of long non-coding RNA, MALAT1 in
complex with KDM5B. c Post-SCULPTing rendering of the KDM5B-MALAT1 complex. d Mol script/R3D Input representation of the complex, show
KDM5B wrapped around MALAT1. e Heat map of KDM5B-MALAT1 interaction using the catRAPID graphic. Interaction propensity is measured in
procedure defined unit, p.d.u. f, g Interaction strength based on interaction propensity rank of binding regions in the positive set (10201 interacting
pairs) using catRAPID strength; Error bars, S.E
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miRs in the KDM5B-overexpressing cells (data not
provided). In addition, the ectopic expression of
KDM5B and its downstream effector gene, MALAT1,
inversely corrected with that of hsa-miR-448 in the
triple negative breast cancer cells (Fig. 8d–f ). Theseresults were indicative of hsa-miR-448 critical role in
the negative regulation of KDM5B expression and
consequently, TNBC progression. Validative experi-
ments showing that hsa-miR-448 improves clinical
outcome and enhances chemosensitivity in breast car-
cinoma, in vivo, are already ongoing.
Fig. 8 KDM5B is a functional target of hsa-miR-448 in TNBC cells. a KDM5B, MALAT1 and hsa-miR-448 protein or nucleotide input sequence
obtained from the National Center for Biotechnology Information (NCBI) database, http://www.ncbi.nlm.nih.gov/. b Predicted KDM5B 3′-UTR
binding site for hsa-miR-448. The hsa-miR-448 seed region alignment with KDM5B 3′-UTR is shown. c Upper panel: Sequence-based prediction of
KDM5B-hsa-miR-448 interaction, with random forest, RF classifier score of 0.7 and support vehicle machine, SVM classifier score of 0.81. Lower
panel: Sequence-based predicted interaction of KDM5B-MALAT1-hsa-miR-448, with RF classifier score of 0.75 and SVM classifier score of 0.997.
* Interaction probabilities generated by RPISeq range from 0 to 1. In performance evaluation experiments, predictions with probabilities > 0.5 were
considered “positive,” i.e., indicating that the corresponding RNA and protein are likely to interact. d The effect of KDM5B knockdown on the
expression of KDM5B transcripts using qRT-PCR. e Loss of KDM5B function altered hsa-miR-448 mRNA expression in MDA-MB-231 cells. MDA-MB-231
cells were infected with scramble (231 V), shKDM5B clone II (231 II) or clone III (231 III) for 72 h. The transcript levels of KDM5B and hsa-miR-448 were
assessed by qRT-PCR. f The mRNA expression of KDM5B and hsa-miR-448 is inversely correlated. Data are representative of 3 independent experiments
and analyzed by student’s t-test. All data are shown as mean ± SEM. **p < 0.01, ***p < 0.001
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Triple negative breast cancer (TNBC) defines a group of
hormone-deficient breast carcinoma associated with very
aggressive tumor biology, dearth of documented targeted
therapy and almost invariably, unfavourable clinical
outcome [29]. Recently, the identification, validation and
integration of novel biomarkers with current diagnostic
or prognostic practices in TNBC clinics have been the
subject of several studies, with the aim of proffering bet-
ter patient stratification and more effective therapeutic
strategy. In this study, we demonstrated the critical roles
of KDM5B and its downstream target MALAT1 in triple
negative breast cancer metastatic phenotype and clinical
prognosis, based on the following observations: (i.)
KDM5B was more abundant in the proteome of the
highly metastatic TNBC cells, (ii.) KDM5B was over-
expressed in highly invasive TNBC MDA-MB-231 and
other metastatic cell lines, than in non-invasive MCF-7
and non-tumorigenic MCF-10A cells, (iii.) KDM5B abla-
tion attenuated tumor cell migration, invasion, clonogeni-
city, and mammosphere formation ability of breast cancer
cells, (iv.) KDM5B-silencing suppressed MALAT1 expres-
sion and inhibited cell proliferation, and (v.) human breast
carcinoma samples exhibited the highest expression of
KDM5B and MALAT1 in advanced stage (T3 and T4)
cancer with associated poorer overall survival. These find-
ings were concordant with our hypotheses that KDM5B
through the modulation of MALAT1 expression is associ-
ated with breast tumorigenesis, progression and poor
prognosis.
Recently, the role of epigenetic regulation in breast
cancer biology, especially that of the histone lysine
demethylases (KDMs), has been the subject of several
studies [30]. This group of chromatin structure modi-
fiers are increasingly shown to facilitate several steps of
cancer progression. Several KDMs, including KDM5B
have been implicated in tumor growth, angiogenesis, in-
vasion, metastasis, and more recently, in tumor-related
chemoresistance [31, 32]. KDM5B, a member of the
JmjC/ARID domain-containing protein family, with re-
stricted tissue distribution, specifically removes methyl
residues from methylated lysine 4 of histone 3 (H3K4),
consequently repressing gene transcription. This repres-
sion is through the discriminate binding of the AT-rich
interactive domain (ARID) of KDM5B to CG-rich DNA
sites, or its interaction with proteins at the DNA binding
domain [33, 34]. In contrast to its physiologically low ex-
pression in normal adult tissue, except in the testes
where it is highly expressed, aberrant expression of
KDM5B has been demonstrated in skin, lung, prostate,
bladder and recently in breast cancer tissues and cell
lines, while KDM5B gene silencing, similar to knock-
down of KDM3A, was shown to cause a significant G1/S
transitional lag in MCF-7 breast tumor cells, suggestingits proliferative and tumorigenic activity [35–39]. Similar
to KDM1A, KDM5B is involved in the silencing of
breast tumor suppressors, including BRCA 1 [40], BRCA
2 [41], pRB [42], CAV1 [43], HOXA5 [44] and SFN [45],
in addition to its active role in the signal transduction of
hormone-regulated organs such as the ovaries, testes
and breasts of gravid females, as well as, in transcrip-
tional activation of androgen receptor (AR) [31, 33].
Recent studies have shown that the dissemination of
malignant cells, as well as disease recurrence, is linked
to the activity of a small subpopulation of cancer cells be-
lieved to possess tumor-growth initiating abilities [46, 47].
Based on the role of KDM5B in cancer stem cell-like
events such as cell fate determination, self-renewal and
enhanced cell motility [48, 49], we hypothesized that
KDM5B is actively involved in the highly metastatic
phenotype of TNBC cells.
Our immunohistochemistry analysis of metastatic hu-
man breast cancer samples indicated a positive correlation
between KDM5B expression, advanced tumor stage and
poor clinical outcome of patients (Figs. 1 and 2). This is
suggestive of KDM5B’s ability to enhance tumor cell inva-
sion, facilitate their homing and increase the clonogenicity
of KDM5B-expressing cells. It is thus not unlikely that
secondary site colonization by highly metastatic TNBC
cells involves the active participation of KDM5B and its
functional substrate, MALAT1. Our data revealed a cor-
relative association between the expression and/or activity
of KDM5B, MALAT1 and that of MALAT1-regulated ef-
fector genes, vimentin and snail (Figs. 3 and 5). In parallel
experiments, KDM5B ablation downregulated MALAT1
expression and also blocked the MALAT1-induced ex-
pression of snail and vimentin (Fig. 6). Taken together,
these data show that KDM5B via modulation of MALAT1
activity plays a critical role in the maintenance of TNBC
invasive phenotype, and that the KDM5B–MALAT1 sig-
nalling axis regulates the activity of the metastatic EMT
factors, such as snail and vimentin. These findings are
consistent with previous findings in which MALAT1 was
shown to positively modulated tumor cell motility by con-
comitantly regulating motility factors, including snail and
vimentin [50, 51].
Furthermore, to validate the structural feasibility of
KDM5B-MALAT1 complex formation, we used the GUI
PyMOL software to demonstrate ligand docking coupled
with limited binding site analysis (Fig. 7). In addition, we
utilized the catRAPID graphic and strength RNA-
protein interaction validation tool for confirmation of
KDM5B-MALAT1 complex formation with KDM5B-
MALAT1 interaction strength of 93 % (Fig. 7) based on
interaction propensity rank of binding regions in the
positive set (10201 interacting pairs). We propound that
targeting these factors of breast tumor aggression, or
their regulatory genes, might be a more effective
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ease recurrence in breast cancer patients.
MicroRNAs (miRs) play very critical roles in the regu-
lation of many eukaryotic genes and their associated bio-
processes, however, epigenetic dysregulation of these
miR activity or expression has been implicated in several
human carcinomas including breast carcinoma [52]. Dif-
ferential expression of miRs in tumor versus non-tumor
tissues, tumor tissue groups with varying degrees of in-
vasiveness, or amongst tumor samples with favourable
compared to poor clinical outcome, currently serve as
vital template for the generation of miR signatures with
potential diagnostic and/or prognostic value. Neverthe-
less, the biofunctional relevance of aberrant miR expres-
sion in triple negative breast carcinoma remained largely
underexplored. Thus, we evaluated the interaction be-
tween KDM5B and the miR, hsa-miR-448.
Our results demonstrate that the expression of hsa-
miR-448 is inversely correlated with that of KDM5B
(Fig. 8). Mechanistically, miRs suppress the expression
of their target genes by effecting proximity and facilitating
interaction between RNAi-induced silencing complex
(RISC) effector proteins and complementary sequences of
the target mRNA [53]. In compliance with the consensual
miRNA - mRNA rule of functional binding, nucleotide 2
to 7 of the 5′ region of hsa-miR-448 served as the inter-
action ‘seed’ region. The seed match of this evolutionarily
conserved region of hsa-miR-448 bonding in a comple-
mentary manner with nucleotides in the 3′ untranslated
region (3′UTR) of KDM5B was sufficient for KDM5B
mRNA recognition and eventual degradation (Fig. 8). On
the molecular level, we demonstrated that this process
combines inhibition of translation, and mRNA degrad-
ation. Our data show that hsa-miR-448, with as little as 6
base pair (bp) match, significantly suppressed KDM5B ex-
pression (Fig. 8). Consistent with emerging model of miR-
mediated gene silencing [54, 55], it is probable that this
hsa-miR-448-induced suppression of KDM5B expression
is sequel to the deadenylation and exonucleolytic cleavage
of KDM5B mRNA.
We are not unaware of the limitations associated with
the use of differential gene expression in the identifica-
tion of miR targets, such as their link with several indir-
ect alterations in transcript abundance, however, this
pattern of gene expression utility in the identification of
miR targets is in compliance with several seminal re-
ports, including that which indicates that over 84 % of
miR-mediated gene suppression was due to reduced
mRNA levels [56–58].
Conclusion
Unravelling the molecular mechanism of KDM5B expres-
sion in TNBC cells remains a work in progress, however,
taken together, our findings indicate that KDM5B is anepigenetic modulator of MALAT1 activity and its down-
stream effector genes, SNAI and vimentin, as well as plays
a critical role in tumor invasion, survival, and niche
colonization by the highly metastatic TNBC cells. We
demonstrated that KDM5B is a surrogate prognostic bio-
marker of breast cancer progression and represents a
therapeutic target in metastatic breast cancer. Further-
more, we showed that the microRNA, hsa-miR-448
significantly inhibits MALAT-mediated oncogenic and
metastatic potential by directly suppressing the expression
of KDM5B in triple negative breast cancer, thus, alluding
to the clinicopathophysiologic relevance of these findings.
The dearth of an effective TNBC anticancer therapy ne-
cessitates the development of new therapeutic strategies
such as miR replacement therapy. We posit that systemic
hsa-miR-448 inoculation, targeting the expression and/or
activities of KDM5B may be a stride in the right direction
in combating the menace of triple negative breast cancer.
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